- Previous Close
0.1050 - Open
0.1100 - Bid 0.1000 x --
- Ask 0.1100 x --
- Day's Range
0.1050 - 0.1100 - 52 Week Range
0.0850 - 0.1850 - Volume
435,541 - Avg. Volume
390,089 - Market Cap (intraday)
39.453M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.20
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
www.bcaldiagnostics.comRecent News: BDX.AX
View MorePerformance Overview: BDX.AX
Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDX.AX
View MoreValuation Measures
Market Cap
39.45M
Enterprise Value
34.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-206.58%
Return on Assets (ttm)
-36.51%
Return on Equity (ttm)
-92.74%
Revenue (ttm)
3.1M
Net Income Avi to Common (ttm)
-6.4M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
6.47M
Total Debt/Equity (mrq)
17.74%
Levered Free Cash Flow (ttm)
-3.61M